Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2010 | 5 | 6 | 683-690
Tytuł artykułu

The effects of immunosuppressive agents on inflammatory response in septic rats

Treść / Zawartość
Warianty tytułu
Języki publikacji
Sepsis remains a serious clinical problems resulting in high morbidity and mortality. We aimed to investigate the inflammatory response in a septic rat model treated with immunomodulator agents. We used the cecal ligature and puncture model to establish septic peritonitis in rats. Male Wistar-Albino rats were randomized into groups of seven rats each and assigned different regimens: Tacrolimus 1 mg/kg/day, cyclosporin-A 5 mg/kg/day and methylprednisolone 15 mg/kg/day. These immunsuppressive agents were applied at the 6 and 48 hour intraperitoneally. The animals were euthanized after 6 and 48 hours and systemic parameters including, IL-2, IL-6, TNF-a, CRP, AST and creatinine were examined. Our study demonstrated that the experimental peritonitis model caused a meaningful rise in the values of systemic parameters. This was especially apparent for early-applied cyclosporin A; in addition, tacrolimus significantly decreased the levels both at the 6 and 48 hour. The excess immune response in complex sepsis treatment might be restrained using immunosuppressive agents administered early. Although additional supportive, comprehensive, experimental and clinical studies are still needed, this therapy model may prove to be an alternative for the future.

Opis fizyczny
  • Gulhane Military Medical Academy, Haydarpasa Teaching Hospital, Department of General Surgery, 34668, Uskudar, Istanbul, Turkey,
  • Department of General Surgery, Corlu Military Hospital, 59850, Corlu, Tekirdag, Turkey
  • Gulhane Military Medical Academy, Haydarpasa Teaching Hospital, Department of General Surgery, 34668, Uskudar, Istanbul, Turkey
  • Gulhane Military Medical Academy, Haydarpasa Teaching Hospital, Department of General Surgery, 34668, Uskudar, Istanbul, Turkey
  • Gulhane Military Medical Academy, Haydarpasa Teaching Hospital, Department of General Surgery, 34668, Uskudar, Istanbul, Turkey
  • Gulhane Military Medical Academy, Haydarpasa Teaching Hospital, Department of General Surgery, 34668, Uskudar, Istanbul, Turkey
  • [1] Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., et al., Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine, Chest., 1992, 101, 1644–1655 [Crossref]
  • [2] Vincent J.L., Abraham E., The last 100 years in sepsis, Am. J. Resp. Crit. Care. Med., 2006, 173, 256–263[Crossref]
  • [3] Kirkeboen K.A., Strand O.A., The role of nitric oxide in sepsis-an overview, Acta. Anaesthesiol. Scand., 1999, 43, 275–288[Crossref]
  • [4] Tekin A., Kucukkartallar T., Turkyilmaz S., Dinckan A., Esen H., Ateš B., et al., Effects of caffeic acid phenethyl ester (CAPE) on sepsis in rats, Inflammation., 2008, 31, 273–280[Crossref][WoS]
  • [5] Casey L.C., Balk R.A., Bone R.C., Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome, Ann. Intern. Med., 1993, 119, 771–778
  • [6] Baue A.E., Durham R., Faist E., Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle?, Shock., 1998, 10, 79–89[Crossref]
  • [7] Davies M.G., Hagen P.O., Systemic inflammatory response syndrome, Br. J. Surg., 1997, 84, 920–935[Crossref]
  • [8] Mulligan M.S., Warner R.L., Foreback J.L., Shanley T.P., Ward P.A., Protective effects of IL-4, IL-10, IL-2 and IL-13 in IgG immune complex-induced lung injury: role of endogenous IL-12, J. Immunol., 1997, 159, 3483–3489
  • [9] Pugin J., Widmer M.C., Kossodo S., Liang C.M., Preas HL 2nd., Suffredini A.F., Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators, Am. J. Respir. Cell. Mol. Biol., 1999, 20, 458–464 [Crossref]
  • [10] Levy G.A., Long-term immunosuppression and drug interactions, Liver. Transpl., 2001, 7, S53–59[Crossref]
  • [11] Ellis R.A., Brenner M.J., Mackinnon S.E., Myckatyn T.M., Hunter D.A., Use of mixed lymphocyte reaction to identify subimmunosuppressive FK-506 levels in mice, Microsurgery, 2003, 23, 276–282[Crossref]
  • [12] Freeman B.D., Natanson C., Anti-inflammatory therapies in sepsis and septic shock, Expert. Opin. Investig. Drugs., 2000, 9, 1651–1663[Crossref]
  • [13] Fernandes D., Duma D., Assreuy J., Steroids and nitric oxide in sepsis, Front. Biosci., 2008, 13, 1698–1710[Crossref][WoS]
  • [14] Wichterman K.A., Baue A.E., Chaudry I.H., Sepsis and septic shock-a review of laboratory models and a proposal, J. Surg. Res., 1980, 29, 189–201[Crossref]
  • [15] Saito H., Sherwood E.R., Varma T.K., Evers B.M., Effects of aging on mortality, hypothermia, and cytokine induction in mice with endotoxemia or sepsis, Mech. Ageing. Dev., 2003, 124, 1047–1058[Crossref]
  • [16] Fauvel H., Marchetti P., Obert G., Joulain O., Chopin C., Formstecher P., et al., Protective effects of cyclosporin A from endotoxin-induced myocardial dysfunction and apoptosis in rats, Am. J. Respir. Crit. Care. Med., 2002, 165, 449–455
  • [17] Bone R.C., Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation, Crit. Care. Med., 1998, 24, 163–172[Crossref]
  • [18] Blackwell T.S., Christman J.W., Sepsis and cytokines: current status, Br. J. Anaesth., 1996, 77, 110–117
  • [19] Scott M.J., Godshall C.J., Cheadle W.G., Jaks, STATs, Cytokines, and Sepsis, Clin. Diagn. Lab. Immunol., 2002, 9, 1153–1159
  • [20] Moore F.A., Sauaia A., Moore E.E., Haenel J.B., Burch J.M., Lezotte D.C., Postinjury multipl organ failure: a bimodel phenomenon, J. Trauma., 1996, 40, 501–510[Crossref]
  • [21] Oberholzer A., Oberholzer C., Moldawer L.L., Sepsis syndromes: understanding the role of innate acquired immunity, Shock., 2001, 16, 83–96[Crossref]
  • [22] Goto T., Kino T., Hatanaka H., Okuhara M., Kohsaka M., Aoki H., et al., FK 506: historical perspectives, Transplant. Proc., 1991, 23, 2713–2717
  • [23] Spijkstra J.J., Girbes A.R., The continuing story of corticosteroids in the treatment of septic shock, Intensive. Care. Med., 2000, 26, 496–500[Crossref]
  • [24] Meduri G.U., Tolley E.A., Chrousos G.P., Stentz F., Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocoticoids, Am. J. Respir. Crit. Care. Med., 2002, 165, 983–991
  • [25] Cannon J.G., Tompkins R.G., Gelfand J.A., Michie H.R., Stanford G.G., van der Meer J.W., et al., Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever, J. Infect. Dis., 1990, 161, 79–84
  • [26] Viallon A., Zeni F., Pouzet V., Lambert C., Quenet S., Aubert G., et al., Serum and ascitic procalcitonin levels in cirrhotic patients with spontaneous bacterial peritonitis: diagnostic value and relationship to proinflammatory cytokines, Intensive. Care. Med., 2000, 26, 1082–1088[Crossref]
  • [27] Garcia-Criado F.J., Palma-Vargas J.M., Valdunciel-Garcia J.J., Toledo A.H., Misawa K., Gomez-Alonso A., et al., Tacrolimus (FK-506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia, Transplantation., 1997, 64, 594–598[Crossref]
  • [28] Koshika T., Ishizaka A., Nagatomi I., Sudo Y., Hasegawa N., Goto T., Pretreatment with FK-506 improves survival rate and gas exchange in canine model of acute lung injury, Am. J. Respir. Crit. Care. Med., 2001, 163, 79–84
  • [29] Giannoudis P.V., Smith R.M., Banks R.E., Windsor A.C., Dickson R.A., Guillou P.J., Stimulation of inflammatory markers after blunt trauma, Br. J. Surg., 1998, 85, 986–990[Crossref]
  • [30] Wakefield C.H., Barclay G.R., Fearon K.C., Goldie A.S., Ross J.A., Grant I.S., et al., Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra-abdominal sepsis. Scottish Sepsis Intervention Group, Br. J. Surg., 1998, 85, 818–825[Crossref]
  • [31] Giffen P.S., Turton J., Andrews C.M., Barrett P., Clarke C.J., Fung K.W., et al., Markers of experimental acute inflammation in the Wistar Han rat with particular reference to haptoglobin and C-reactive protein, Arch. Toxicol., 2003, 77, 392–402[Crossref]
  • [32] Küster H., Weiss M., Willeitner A.E., Detlefsen S., Jeremias I., Zbojan J., et al., Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation, Lancet., 1998, 352, 1271–1277[Crossref]
  • [33] Gorantla V.S., Barker J.H., Jones J.W. Jr., Prabhune K., Maldonado K., Granger D.K., Immunosuppressive agents in transplantation: mechanisms of action and current anti-rejection strategies, Microsurgery., 2000, 20, 420–429<420::AID-MICR13>3.0.CO;2-O[Crossref]
  • [34] Edremitlioglu M., Kilic D., Oter S., Kisa U., Korkmaz A., Coškun O., et al., The effect of hyperbaric oxygen treatment on the renal functions in septic rats: relation to oxidative damage, Surg. Today., 2005, 35, 653–661[Crossref]
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.